Researchers from Vanderbilt-Ingram Cancer Center discovered that T-cells recognizing the cardiac antigen α-myosin are the mechanism for immunotherapy-related myocarditis.
In the largest study of its kind, researchers from The University of Texas MD Anderson Cancer Center identified three subgroups of patients with large B-cell lymphoma who have different levels of benefit from CD19 chimeric antigen receptor T cell therapy.
